Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALGB 40101: AC vs Paclitaxel in Breast Cancer
NCT00041119Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2002
- Primary completion
- Apr 2012
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection in breast cancer (4 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Disease-Free Survival at 6.4 years and Relapse Free Survival at 4 years. Started May 2002; status: completed.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00041119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041119.